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Abstract
Summary In this retrospective cohort study using the Clinical
Practice Research Datalink (CPRD), patients with sarcoidosis
have an increased risk of clinical vertebral fractures and when
on recent treatment with oral glucocorticoids, also an in-
creased risk of any fractures and osteoporotic fractures.
Introduction Sarcoidosis is a chronic inflammatory disease, in
which fragility fractures have been reported despite normal
BMD. The aim of this study was to assess whether patients
with sarcoidosis have an increased risk of clinical fractures
compared to the general population.
Methods A retrospective cohort study was conducted using
the CPRD. All patients with a CPRD code for sarcoidosis
between January 1987 and September 2012 were included.
Cox proportional hazards models were used to derive adjusted
relative risks (RRs) of fractures in all sarcoidosis patients com-
pared to matched controls, and within the sarcoidosis group
according to use and dose of systemic glucocorticoids.
Results Five thousand seven hundred twenty-two sarcoidosis
patients (mean age 48.0 years, 51 % females, mean follow-up
6.7 years) were identified.
Compared to 28,704 matched controls, the risk of any frac-
ture was not different in patients with sarcoidosis. However,
the risk of clinical vertebral fractures was significantly in-
creased (adj RR 1.77; 95 % CI 1.06–2.96) and the risk of
non-vertebral fractures was decreased although marginally
significant (adj RR 0.87; 95 % CI 0.77–0.99). Compared to
sarcoidosis patients not taking glucocorticoids, recent use of
systemic glucocorticoids was associatedwith an increased risk
of any fracture (adj RR 1.50; 95 % CI 1.20–1.89) and of an
osteoporotic fracture (adj RR 1.47; 95 % CI 1.07–2.02).
Conclusions Patients with sarcoidosis have an increased
risk of clinical vertebral fractures, and when using gluco-
corticoid therapy, an increased risk of any fractures and
osteoporotic fractures. In contrast, the risk of non-
vertebral fractures maybe decreased. Further investigation
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is needed to understand the underlying mechanisms of
these contrasting effects on fracture risk.
Keywords Bone . Epidemiology . Fractures .
Glucocorticoids . Osteoporosis . Sarcoidosis
Introduction
Sarcoidosis is a multi-organ, chronic inflammatory, granulo-
matous disorder that can affect almost any organ of the body.
It may occur at any age, but most frequently in adults younger
than 50 years. It is more common in women and certain racial
groups, such as African–Americans and northern Europeans
[1–4]. Around 300–400 new cases of sarcoidosis are diag-
nosed per year in the UK [5].
Bone mineral density (BMD) is decreased and the risk of
clinical and radiological vertebral fractures is increased in
chronic inflammatory diseases such as asthma and chronic
obstructive pulmonary disease (COPD) [6, 7], rheumatoid ar-
thritis [8–10], ankylosing spondylitis [11, 12], systemic lupus
erythematosus [13], and inflammatory bowel disease [14]. In
addition, treatment with glucocorticoids has been associated
with a dose-dependent increase in fracture risk [9, 15–17], at a
higher level of BMD than in patients who do not use
glucocorticoids.
In patients with sarcoidosis, small cohort studies have dem-
onstrated a high prevalence of fragility fractures (23.5 %) [18]
and radiographic vertebral fractures (20–30 %) [19], with an
increase of incidence (up to 32%) of vertebral fractures during
follow-up [20]. In contrast, BMD has been found to be normal
in most patients with sarcoidosis [19, 21–24] and BMD did
not change over time [20, 25]. Furthermore, the effect of glu-
cocorticoids on bone might be reversible [26, 27]. No studies
are available that investigated the prevalence of vertebral and
non-vertebral fractures in patients with sarcoidosis compared
to a control population and the effect of glucocorticoid therapy
on fracture risk in sarcoidosis.
The first objective of this study is to determine whether
patients with sarcoidosis have an increased risk of clinical
fractures compared to the general population. The second ob-




A retrospective cohort study was conducted using the
Clinical Practice Research Datalink (CPRD), formerly
known as the General Practice Research Database. The
CPRD contains computerized medical records of 625
primary care practices in the UK, representing 8 % of the
British population. The database provides detailed informa-
tion on demographics, drug prescriptions, clinical events,
specialist referrals, and hospital admissions. Previous studies
of CPRD data have shown a high level of data validity with
respect to the reporting of fractures (>90 % of fractures were
confirmed) [16]. The protocol number is 2010_060.
Study population
All patients with a CPRD read code for sarcoidosis during the
study period (from January 1987 through September 2012)
were included in the study population. In order to ascertain a
more probable diagnosis of sarcoidosis, these patients were
stratified into probable and possible cases of sarcoidosis.
Probable cases had at least one sarcoidosis CPRD record
and any of the following: (1) treatment with methotrexate,
azathioprine, leflunomide, chloroquine, hydroxychloroquine,
and systemic/inhaled glucocorticoids at any time during fol-
low-up, (2) two or more subsequent diagnoses of sarcoidosis,
and/or (3) a specialist diagnosis of sarcoidosis. All other sar-
coidosis patients were defined as possible cases. The index
date was defined as the first record for sarcoidosis. Each pa-
tient was matched by age, sex, calendar time, and practice to
up to four patients without a history of sarcoidosis ever during
the study period.
Outcomes
All patients had a follow-up from the index date to either the
end of data collection, the date of transfer of the patient out of
the practice area, the patient’s death, or fracture (GPRD read
codes), whichever came first.
Earlier studies have demonstrated that there is a high level
of data validity with respect to reporting of fractures from
CPRD databases and >90 % of reported fractures were con-
firmed [16].
The primary outcome of this study was to determine
whether patients with sarcoidosis have an increased risk
of clinical fractures compared to the general population.
For additional analyses, fracture type was stratified accord-
ing to the WHO Fracture Risk Assessment Tool into oste-
oporotic (spine, hip, forearm, or humerus fracture), and
non-osteoporotic fractures (all other fractures) and also
stratified into vertebral and non-vertebral fractures. The sec-
ond objective was to estimate their fracture risk, stratified
by glucocorticoid use.
Potential confounders
Total follow-up was divided into 30-day intervals.
Before the start of each 30-day interval, the presence
of general risk factors for fracture was evaluated. At
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baseline, information was available about age, sex,
smoking status, body mass index, alcohol use, a record
of falls in the previous 6–12 months, and a history of
fracture. Furthermore, we assessed if there was a history
of a chronic disease (rheumatoid arthritis, cerebrovascu-
lar disease, heart failure, inflammatory bowel disease,
asthma/chronic obstructive pulmonary disease, secondary
osteoporosis, anaemia, and dementia). Prescriptions for
glucocorticoids (systemic and local separately), hypnot-
ic/anxiolytic, antipsychotic, antidepressant, proton pump
inhibitor, antidiabetic, or antiepileptic agents, as well as
drugs for the treatment of Parkinson’s disease, in the
6 months before inclusion, were recorded.
For each sarcoidosis patient, the use of systemic glu-
cocorticoids in the previous 6 months before inclusion
was evaluated. Systemic glucocorticoid users were fur-
ther stratified according to their average and cumulative
dose using the World Health Organisation’s defined dai-
ly dosages (DDD) [28]. Exposure was expressed as oral
prednisone equivalents. For the cumulative exposure, all
prescriptions of the most recent treatment period
(allowing a maximum non-use gap of 6 months between
two prescriptions) were considered. For the average dai-
ly dose, the cumulative exposure of the most recent
treatment period was divided by the number of days
between start and end of the treatment period. When
data on the prescribed quantity were missing, the medi-
an expected quantity was used.
Statistical analysis
Cox proportional hazards models were used to derive adjusted
relative risks (adj RRs) for fracture (any, osteoporotic, and
non-osteoporotic) in sarcoidosis patients compared with
matched control subjects (SAS 9.2, PHREG procedure).
Potential confounders were entered into the final model if they
independently changed the beta coefficient by at least 5 %.
This main analysis was repeated for possible and probable
cases of sarcoidosis. For all other analyses, the full cohort of
sarcoidosis patients (probable and possible cases) was used.
Within sarcoidosis patients, the individuals were stratified ac-
cording to their cumulative and average daily dose of systemic
glucocorticoid exposure. Furthermore, absolute incidence
rates for fractures in sarcoidosis patients and matched controls
were calculated.
Timing of fracture occurrence following first sarcoidosis
record was examined by including time interaction terms
into the model for the following time intervals: < 6 months,
6–12 months, 1–2 years, 2–5 years, 5–10 years, and
>10 years. Using smoothing spline regression, the time
trend for risk of fracture for these given time intervals
was visualized.
Results
We identified 5722 sarcoidosis patients along with 28,704
age- and sex-matched controls (mean age 48.0 years, 51 %
females), with a mean follow-up of 6.7 years per patient.
Baseline characteristics of patients with sarcoidosis and age-
and sex-matched controls are shown in Table 1. There were
substantially fewer smokers among the sarcoidosis patients
than in the matched controls (current smokers 13.8 vs.
25.4 %). Furthermore, patients with sarcoidosis were more
likely to have used medical drugs in the previous 6 months,
in particular systemic/local glucocorticoids, antidiabetics, an-
tidepressants, benzodiazepines, and calcium/vitamin D sup-
plements. Bisphosphonate use was higher among sarcoidosis
patients (4.3 %) compared to matched controls (1.0 %),
whereas no differences were observed for use of HRT and
other antiosteoporotic drugs.
In the sarcoidosis cohort, 406 patients had at least one
fracture; 203 osteoporotic fractures occurred (37 clinical ver-
tebral fractures, 22 hip fractures, 144 other osteoporotic frac-
tures, i.e., forearm or humerus fractures) and 263 non-
osteoporotic fractures (Table 2). There was no difference be-
tween patients with sarcoidosis and matched controls in the
risk of any fracture (adj RR 0.90; 95 % CI 0.80–1.02), an
osteoporotic fracture (adj RR 1.02, 95 % CI 0.85–1.23) or
non-osteoporotic fracture (adj RR 0.89, 95 % CI 0.76–1.03).
Further adjustments for antiosteoporotic drugs did not alter the
relative risk estimates (e.g., for any fracture: HR 0.91 (95%CI
0.81–1.03). The risk of clinical vertebral fractures was signif-
icantly increased in patients with sarcoidosis (adj RR 1.77;
95 % CI 1.06–2.96), and the risk for non-vertebral fractures
was decreased (adj RR 0.87; 95 % CI 0.77–0.99).
The adj RR was not modified by the sarcoidosis case def-
inition (possible sarcoidosis: adj RR 0.92; 95% CI 0.76–1.13;
probable sarcoidosis: adj RR 0.89; 95 % CI 0.76–1.04 for any
fracture) and there was no statistical interaction with age, sex,
or type of fracture. When plotted against time since diagnosis,
the risk of any fracture was temporarily decreased during the
first years after diagnosis, but was not different during longer
follow-up (Fig. 1).
Use of systemic glucocorticoids in the previous 6 months
increased the risk of any facture (adj RR 1.50; 95 % CI 1.20–
1.89) and of an osteoporotic fracture (adj RR 1.47; 95 % CI
1.07–2.02) compared to no use of systemic glucocorticoids
(Table 3). The risk of any fracture and of an osteoporotic
fracture increased already with a daily dose of <5 mg predni-
sone equivalents per day (adj RR 1.49; 95%CI 1.12–1.97 and
adj RR 1.52; 95 % CI 1.04–2.23 for any and osteoporotic
fracture, respectively) and with the lowest cumulative doses
(<1820mg; adj RR 1.67; 95% CI 1.08–2.59 and adj RR 2.02;
95 % CI 1.14–3.59 for any and osteoporotic fracture, respec-
tively). The fracture risk did not increase significantly with
higher dose or higher cumulative dose.
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Table 1 Baseline characteristics of sarcoidosis patients and matched controls
Characteristic Sarcoidosis patients Matched controls
N=5722 Percent N=28,704 Percent
Follow-up (years, mean, SD) 6.7 (5.2) 6.7 (5.2)
Females 2918 (51.0) 14,637 (51.0)
Age (years, mean, SD) 48.0 (13.4) 48.0 (13.4)
18–39 years 1691 (29.6) 8479 (29.5)
40–59 years 2847 (49.8) 14,284 (49.8)
60–79 years 1115 (19.5) 5598 (19.5)
80+ years 69 (1.2) 343 (1.2)
BMI (kg/m2, mean, SD) 27.9 (5.9) 26.8 (5.4)
<20.0 kg/m2 232 (4.1) 1301 (4.5)
20–24.9 kg/m2 1468 (25.7) 8745 (30.5)
25.0–29.9 kg/m2 1943 (34.0) 8614 (30.0)
30.0+ kg/m2 1505 (26.3) 5538 (19.3)
Unknown 574 (10.0) 4506 (15.7)
Smoking status
Never 3763 (65.8) 15,215 (53.0)
Current 792 (13.8) 7304 (25.4)
Ex 1041 (18.2) 4537 (15.8)
Unknown 126 (2.2) 1648 (5.7)
Alcohol use
No 1104 (19.3) 4210 (14.7)
Yes 3973 (69.4) 19,972 (69.6)
Unknown 645 (11.3) 4522 (15.8)
Falls (6–12 months before) 230 (4.0) 1050 (3.7)
Fracture ever before 1079 (18.9) 5096 (17.8)
History of disease
Rheumatoid arthritis 79 (1.4) 238 (0.8)
Cerebrovascular disease 111 (1.9) 452 (1.6)
Inflammatory bowel disease 87 (1.5) 237 (0.8)
COPD 157 (2.7) 381 (1.3)
Asthma 923 (16.1) 3008 (10.4)
Hypertension 900 (15.7) 3784 (13.2)
Dementia 21 (0.4) 70 (0.2)
Heart failure 98 (1.7) 199 (0.7)
Drug use within 6 months
Systemic glucocorticoids 953 (16.7) 492 (1.7)
Topical glucocorticoids 618 (10.8) 1782 (6.2)
Antidiabetics 263 (4.6) 810 (2.8)
Anticonvulsants 166 (2.9) 467 (1.6)
Loop diuretics 294 (5.1) 568 (2.0)
Proton pump inhibitors 825 (14.4) 1869 (6.5)
Antipsychotics 59 (1.0) 298 (1.0)
Antidepressants 658 (11.5) 2418 (8.4)
Anxiolytics/hypnotics 360 (6.3) 1166 (4.1)
Calcium/vitamin D 251 (4.4) 412 (1.4)
Bisphosphonates 254 (4.3) 283 (1.0)
Hormone replacement therapy 206 (3.6) 1093 (3.8)
Other antiosteoporotic drugs 1 (0.0) 6 (0.0)
BMI body mass index, SD standard deviation
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Discussion
In this large population-based study, patients with sar-
coidosis had an increased risk of clinical vertebral frac-
tures compared to matched controls and, when on recent
therapy with systemic glucocorticoids, an increased risk
of any fractures and osteoporotic fractures. In contrast,
the risk of non-vertebral fractures was decreased, al-
though marginally significant. To our knowledge, this
study is the first population-based study that assessed
vertebral and non-vertebral fracture risk in patients with
sarcoidosis compared to matched control subjects.
The risk of clinical vertebral fractures was increased,
which is in line with findings in other inflammatory
diseases such as rheumatoid arthritis [9, 29, 30], anky-
losing spondylitis [11, 12], SLE [13, 31], COPD [6, 7]
and inflammatory bowel disease [14]. Possible explana-
tions for the increased vertebral fracture risk can be
found in other studies regarding patients with sarcoido-
sis, such as the finding of a decreased trabecular BMD
within the vertebrae [26], a decreased BMD in the spine
in postmenopausal women [22], and an increased bone
resorption [19]. In spite of the increased risk of clinical
vertebral fractures in patients with sarcoidosis, the total
number of vertebral fractures was low. This is in con-
trast with other studies in patients with sarcoidosis
where vertebral fractures were assessed by systemic ra-
diographic evaluation [19, 20], suggesting that most ra-
diographic vertebral fractures are not accompanied by
typical signs and symptoms of an acute vertebral frac-
ture. This is also the case for vertebral fractures in
postmenopausal osteoporosis [32, 33].
The decreased adjusted risk of non-vertebral fractures in
our study is an unexpected finding and only marginally statis-
tically significant. It is in contrast with the increased risk of
Table 2 Risk of fracture in sarcoidosis patients compared with matched controls, stratified by age, sex, and type of fracture
Person years Fracture
Events Age–sex adj RR (95 % CI) Adj RR (95 % CI) (a)
No sarcoidosis 183,514 1815 Reference Reference
Sarcoidosis
Any fracture 36,760 406 1.14 (1.02–1.27) 0.90 (0.80–1.02)
By age (years)
18–39 7384 48 0.67 (0.49–0.91) 0.60 (0.42–0.85)
40–59 19,763 171 1.17 (0.99–1.39) 0.95 (0.78–1.15)
60–79 9012 166 1.41 (1.18–1.68) 1.07 (0.87–1.31)
80+ 601 21 1.07 (0.64–1.78) 0.97 (0.56–1.67)
By sex
Males 17,529 143 0.98 (0.81–1.18) 0.79 (0.64–0.97)
Females 19,231 263 1.24 (1.08–1.43) 0.97 (0.83–1.13)
Osteoporotic fracture 37,670 203 1.37 (1.17–1.60) 1.02 (0.85–1.23)
Hip fracture 38,397 22 0.93 (0.59–1.48) 0.61 (0.35–1.04)
Vertebral fracturea 38,363 37 3.10 (2.04–4.70) 1.77 (1.06–2.96)
Non-osteoporotic fracture 37,256 263 1.07 (0.93–1.23) 0.89 (0.76–1.03)
Non-vertebral fracturea 36,852 377 1.08 (0.96–1.21) 0.87 (0.77–0.99)
Adjusted for smoking status, a history of heart failure, asthma/COPD, and use of systemic glucocorticoids, calcium/vitamin D supplements, loop
diuretics, benzodiazepines, antidepressants, proton pump inhibitors, and anticonvulsants in the previous 6 months
Adj adjusted, CI confidence interval, RR relative risk
a There were eight patients that sustained both a vertebral and non-vertebral fracture
Fig. 1 Spline regression plot of time since first sarcoidosis record and
risk of any fracture in sarcoidosis patients versus matched controls.
Adjusted for confounders as shown in Table 2
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vertebral fractures in this study and with the increased risk of
non-vertebral fractures in inflammatory rheumatic diseases
such as rheumatoid arthritis [9, 34, 35], ankylosing spondylitis
[36], and JIA [36]. Another study did find a high fracture
incidence in patients with sarcoidosis [18]. However, in the
latter study there was no control population, and the study
population consisted of patients at a pulmonary outpatient
clinic where 62.0 % of patients were treated with glucocorti-
coids (vs. 16.7% in our study). In most studies in patients with
sarcoidosis, BMD was normal in all patients [18, 19, 21, 23,
24] even in those treated with glucocorticoids [18, 19], with
the exception of one study that showed a decreased BMD in
postmenopausal but not in premenopausal women [22]. Why
BMD in the spine and hip is normal in most patients with
sarcoidosis, is unclear and it does not explain the slightly
decreased risk of non-vertebral fractures in patients with sar-
coidosis compared to matched controls.
The increased risk of any and of osteoporotic fractures in
patients with recent use of systemic glucocorticoids is in line
with findings of increased fracture risk in glucocorticoid users
in other inflammatory diseases [15–17]. However, we did not
find a further increase in fracture risk with higher daily or
cumulative doses of glucocorticoids. Treatment of inflamma-
tory diseases for example rheumatoid arthritis results in lower
disease activity and adequate disease control which contrib-
utes to bone protection, even when glucocorticoids are used
[37]. The time relation between onset of sarcoidosis and initial
but not persisting decrease of risk of any fracture indicates that
disease or treatment related factors early in the disease could
play a protective role on non-vertebral fracture risk.
In population-based cohort studies, a relation between CRP
and fracture risk has been reported even after adjustment for
confounding factors [38–40], however this relation could be
U-shaped [41] or only present when CRP was >3 mg/l [42,
43]. In patients with sarcoidosis, however, no correlation was
found between bone turnover markers or CRP and BMD or
fractures [18]. In our study, we did not have additional infor-
mation on markers for inflammation (IL2R, ACE) or disease
activity.
Other factors, such as low dietary calcium intake, low cre-
atinine clearance, and higher 25(OH)D and 1,25(OH) are as-
sociated to an increased fracture risk and bone resorption in
sarcoidosis [18, 44], but no data were available on these pa-
rameters in our study. Besides BMD and bone-related risk
factors, other factors could influence fracture risk in patients
with sarcoidosis. Patients with sarcoidosis have an increased
risk of sarcopenia, which could increase the risk of falls and
bone loss [45]. We did not have information on diagnostic
Table 3 Risk of any and osteoporotic fractures within sarcoidosis patients, stratified by use of drugs
Any fracture Osteoporotic fracture
Events Adj RR (95 % CI)a Events Adj RR (95 % CI)a
By use of systemic glucocorticoids in the previous 6 months (reference=no use)b
No 263 1.00 126 1.00
Yes 143 1.50 (1.20–1.89) 77 1.47 (1.07–2.02)
By average daily dose of systemic glucocorticoid exposure in the previous year, expressed as prednisone equivalents
≤5 mgc 66 1.49 (1.12–1.97) 37 1.52 (1.04–2.23)
5.1–10 mg 45 1.36 (0.97–1.90) 21 1.13 (0.69–1.84)
>10 mg 32 1.88 (1.26–2.79) 19 2.09 (1.24–3.53)
By cumulative dose of systemic glucocorticoid exposure, expressed as prednisone equivalentsd
<1820 mgc 22 1.67 (1.08–2.59) 13 2.02 (1.14–3.59)
1820–7300 mg 41 1.37 (0.97–1.93) 22 1.36 (0.85–2.17)
>7300 mg 80 1.53 (1.16–2.03) 42 1.39 (0.94–2.04)
By use of antidepressants in the previous 6 months (reference–no use)b
No 318 1.00 157 1.00
Yes 88 1.25 (0.97–1.61) 46 1.08 (0.76–1.55)
By use of anxiolytics/hypnotics in the previous 6 months (reference=no use)b
No 364 1.00 176 1.00
Yes 42 1.16 (0.83–1.63) 27 1.37 (0.89–2.12)
Adj adjusted, CI confidence interval, RR relative risk
a Adjusted for confounders shown in footnote Table 2
b Reference=no use in the previous 6 months
c Excluding no use of systemic glucocorticoids in the previous 6 months
d Cumulative amount of all previous systemic glucocorticoid prescriptions
1608 Osteoporos Int (2016) 27:1603–1610
tests for sarcopenia, such as muscle strength and mass. Body
mass index (BMI) in patients with sarcoidosis was not differ-
ent compared to controls. Sarcoidosis can also be localised in
bone, as has been demonstrated by a study with PET scans
which show extensive bone marrow involvement in sarcoid-
osis [46]. Sarcoid granulomas are surrounded by osteoclasts,
but a local focus of osseous sarcoidosis resulting in a fracture
is rare [47]. Pulmonary Wnt signalling is altered in patients
with sarcoidosis [48]; however, whether Wnt signalling in
bone is also altered in patients with sarcoidosis is unknown.
The fact that the risk of clinical vertebral fractures was
increased, whereas the risk of all fractures was not different
compared to matched controls, suggests that sarcoidosis prob-
ably has a negative impact on the trabecular bone without
affecting the cortical bone. The finding of a decreased risk
of non-vertebral fractures in this study was only marginally
significant and in combination with data from literature the
question is whether non-vertebral fracture risk is actually de-
creased in patients with sarcoidosis.
Limitations of our study were the lack of information on
markers for inflammation (IL2R, ACE), disease activity, and
BMD, so we could not adjust for these possible confounders.
In addition, no information was available on muscle strength or
mass and fall risk. The sarcoidosis case definition was described,
but we were not able to confirm the diagnosis based on direct
data from rheumatologists, pulmonologists, or other physicians.
In conclusion, patients with sarcoidosis have an increased
risk of clinical vertebral fractures, and when on recent treat-
ment with oral glucocorticoids, also an increased risk of any
fractures and osteoporotic fractures. The decreased risk of
non-vertebral fractures was an intriguing and unexpected find-
ing, however withmarginal statistical significance, and further
studies should be performed to understand more about the
factors that could protect against bone loss and non-vertebral
fracture risk in sarcoidosis.
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